动脉粥样硬化的病理生理学与治疗：脂蛋白修饰治疗的当前观点与未来展望
Pathophysiology and treatment of atherosclerosis : Current view and future perspective on lipoprotein modification treatment.
作者信息
Bergheanu S C, Bodde M C, Jukema J W
机构信息
Centre for Human Drug Research, Leiden, The Netherlands.
InterEuropa Clinical Research, Rotterdam, The Netherlands.
出版信息
Neth Heart J. 2017 Apr;25(4):231-242. doi: 10.1007/s12471-017-0959-2.
Abstract
Recent years have brought a significant amount of new results in the field of atherosclerosis. A better understanding of the role of different lipoprotein particles in the formation of atherosclerotic plaques is now possible. Recent cardiovascular clinical trials have also shed more light upon the efficacy and safety of novel compounds targeting the main pathways of atherosclerosis and its cardiovascular complications.In this review, we first provide a background consisting of the current understanding of the pathophysiology and treatment of atherosclerotic disease, followed by our future perspectives on several novel classes of drugs that target atherosclerosis. The focus of this update is on the pathophysiology and medical interventions of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG) and lipoprotein(a) (Lp(a)).
摘要
近年来，动脉粥样硬化领域取得了大量新成果。现在有可能更好地理解不同脂蛋白颗粒在动脉粥样硬化斑块形成中的作用。近期的心血管临床试验也进一步揭示了针对动脉粥样硬化主要途径及其心血管并发症的新型化合物的疗效和安全性。在本综述中，我们首先介绍动脉粥样硬化疾病病理生理学和治疗的当前认识背景，随后阐述我们对几类针对动脉粥样硬化的新型药物的未来展望。本次更新的重点是低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）、甘油三酯（TG）和脂蛋白(a) [Lp(a)]的病理生理学和医学干预措施。
相似文献
1
Pathophysiology and treatment of atherosclerosis : Current view and future perspective on lipoprotein modification treatment.
Neth Heart J. 2017 Apr;25(4):231-242. doi: 10.1007/s12471-017-0959-2.
2
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Endocr Pract. 2017 Apr;23(Suppl 2):1-87. doi: 10.4158/EP171764.APPGL.
3
From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
Eur J Prev Cardiol. 2018 Nov;25(17):1843-1851. doi: 10.1177/2047487318792626. Epub 2018 Jul 30.
4
Atherosclerosis Residual Lipid Risk-Overview of Existing and Future Pharmacotherapies.
J Cardiovasc Dev Dis. 2024 Apr 21;11(4):126. doi: 10.3390/jcdd11040126.
5
Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
J Am Coll Cardiol. 2013 Oct 15;62(16):1401-8. doi: 10.1016/j.jacc.2013.07.056. Epub 2013 Aug 21.
6
Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.
Circulation. 2018 Sep 25;138(13):1304-1316. doi: 10.1161/CIRCULATIONAHA.118.034710.
7
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Nutr Metab Cardiovasc Dis. 2016 Oct;26(10):853-62. doi: 10.1016/j.numecd.2016.05.006. Epub 2016 May 30.
8
Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options.
Ann Med. 2020 Aug;52(5):162-177. doi: 10.1080/07853890.2020.1775287. Epub 2020 Jun 8.
9
Acute effect of proprotein convertase subtilisin/kexin type 9 inhibitor on oxidized low-density lipoprotein and lipid profile in patients at cardiovascular risk.
J Clin Biochem Nutr. 2023 Nov;73(3):249-254. doi: 10.3164/jcbn.23-45. Epub 2023 Sep 1.
10
LDL cholesterol-lowering therapies: emphasis on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
Drugs Today (Barc). 2019 May;55(5):329-344. doi: 10.1358/dot.2019.55.5.2976501.
引用本文的文献
1
Atherosclerosis: from lipid-lowering and anti-inflammatory therapies to targeting arterial retention of ApoB-containing lipoproteins.
Front Immunol. 2025 Jun 9;16:1485801. doi: 10.3389/fimmu.2025.1485801. eCollection 2025.
2
Unraveling anti-atherosclerosis mechanism of anthocyanins from Xinjiang wild cherry plum (Prunus divaricata Ledeb) via network pharmacology and molecular docking.
Bioresour Bioprocess. 2025 Jun 6;12(1):53. doi: 10.1186/s40643-025-00900-w.
3
Incidence of Cardiovascular Events in Hypertensive Patients Based on the Quantity of Major Risk Factors According to the Isfahan Cohort Study.
Int J Hypertens. 2025 May 20;2025:3743691. doi: 10.1155/ijhy/3743691. eCollection 2025.
4
Oxidant-Based Cytotoxic Agents During Aging: From Disturbed Energy Metabolism to Chronic Inflammation and Disease Progression.
Biomolecules. 2025 Apr 9;15(4):547. doi: 10.3390/biom15040547.
5
Amelioration of atherosclerotic complications and dyslipidemia by verbascoside-enriched fraction of leaves targeting LDL-R and LXR-mediated reverse cholesterol transport.
Chin Herb Med. 2025 Feb 25;17(2):352-367. doi: 10.1016/j.chmed.2025.02.007. eCollection 2025 Apr.
6
Integration of machine learning and experimental validation reveals new lipid-lowering drug candidates.
Acta Pharmacol Sin. 2025 Apr 15. doi: 10.1038/s41401-025-01539-1.
7
Discussion on the comparison of Raman spectroscopy and cardiovascular disease-related imaging techniques and the future applications of Raman technology: a systematic review.
Lasers Med Sci. 2025 Feb 24;40(1):116. doi: 10.1007/s10103-025-04315-z.
8
The Metabolite Indole-3-Acetic Acid of Bacteroides Ovatus Improves Atherosclerosis by Restoring the Polarisation Balance of M1/M2 Macrophages and Inhibiting Inflammation.
Adv Sci (Weinh). 2025 Mar;12(11):e2413010. doi: 10.1002/advs.202413010. Epub 2025 Jan 22.
9
Endothelial IGFBP6 suppresses vascular inflammation and atherosclerosis.
Nat Cardiovasc Res. 2025 Feb;4(2):145-162. doi: 10.1038/s44161-024-00591-0. Epub 2025 Jan 10.
10
Myeloid GSK3α Deficiency Reduces Lesional Inflammation and Neovascularization during Atherosclerotic Progression.
Int J Mol Sci. 2024 Oct 10;25(20):10897. doi: 10.3390/ijms252010897.
本文引用的文献
1
Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I).
Circulation. 2016 Dec 13;134(24):1918-1930. doi: 10.1161/CIRCULATIONAHA.116.025687. Epub 2016 Nov 15.
2
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
JAMA. 2016 Dec 13;316(22):2373-2384. doi: 10.1001/jama.2016.16951.
3
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
Lancet. 2016 Nov 5;388(10057):2239-2253. doi: 10.1016/S0140-6736(16)31009-1. Epub 2016 Sep 21.
4
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.
Eur Heart J. 2016 Oct 14;37(39):2999-3058. doi: 10.1093/eurheartj/ehw272. Epub 2016 Aug 27.
5
Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials.
Am Heart J. 2016 Aug;178:135-44. doi: 10.1016/j.ahj.2016.05.010. Epub 2016 May 28.
6
Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial.
Am Heart J. 2016 Mar;173:94-101. doi: 10.1016/j.ahj.2015.11.015. Epub 2015 Dec 17.
7
Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial.
Am Heart J. 2015 Dec;170(6):1061-9. doi: 10.1016/j.ahj.2015.09.007. Epub 2015 Sep 16.
8
A cholesterol-lowering VLP vaccine that targets PCSK9.
Vaccine. 2015 Oct 26;33(43):5747-5755. doi: 10.1016/j.vaccine.2015.09.044. Epub 2015 Sep 26.
9
Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.
J Lipid Res. 2015 Nov;56(11):2085-93. doi: 10.1194/jlr.M057794. Epub 2015 Sep 4.
10
Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial.
J Am Coll Cardiol. 2015 Aug 4;66(5):495-507. doi: 10.1016/j.jacc.2015.05.065.
Zotero 插件